1000TiPOPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm). (23rd October 2018) - Poveda, A M; Davidson, R; Blakeley, C; Milner, A